PT1334964E - Processo para a produção de cristais de nateglinida na forma b - Google Patents
Processo para a produção de cristais de nateglinida na forma b Download PDFInfo
- Publication number
- PT1334964E PT1334964E PT01976819T PT01976819T PT1334964E PT 1334964 E PT1334964 E PT 1334964E PT 01976819 T PT01976819 T PT 01976819T PT 01976819 T PT01976819 T PT 01976819T PT 1334964 E PT1334964 E PT 1334964E
- Authority
- PT
- Portugal
- Prior art keywords
- crystals
- nateglinide
- type
- wet
- solvated
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 84
- 229960000698 nateglinide Drugs 0.000 title claims abstract description 42
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 title claims abstract description 20
- 238000001035 drying Methods 0.000 claims abstract description 12
- 238000006243 chemical reaction Methods 0.000 claims abstract description 10
- 239000002904 solvent Substances 0.000 claims abstract description 10
- 238000002425 crystallisation Methods 0.000 claims description 7
- 230000008025 crystallization Effects 0.000 claims description 7
- 238000001816 cooling Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 150000004677 hydrates Chemical class 0.000 claims description 2
- -1 nateglinide hydrates Chemical class 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000012453 solvate Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- OELFLUMRDSZNSF-OFLPRAFFSA-N (2R)-2-[[oxo-(4-propan-2-ylcyclohexyl)methyl]amino]-3-phenylpropanoic acid Chemical compound C1CC(C(C)C)CCC1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-OFLPRAFFSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/38—Separation; Purification; Stabilisation; Use of additives
- C07C227/40—Separation; Purification
- C07C227/42—Crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Crystallography & Structural Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000324375 | 2000-10-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1334964E true PT1334964E (pt) | 2007-09-20 |
Family
ID=18801920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT01976819T PT1334964E (pt) | 2000-10-24 | 2001-10-23 | Processo para a produção de cristais de nateglinida na forma b |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20030229249A1 (enExample) |
| EP (1) | EP1334964B1 (enExample) |
| JP (1) | JP4225057B2 (enExample) |
| KR (1) | KR100810930B1 (enExample) |
| CN (1) | CN100422143C (enExample) |
| AT (1) | ATE370115T1 (enExample) |
| AU (1) | AU2001296001A1 (enExample) |
| BR (1) | BR0114846A (enExample) |
| CA (1) | CA2426745C (enExample) |
| CY (1) | CY1106839T1 (enExample) |
| DE (1) | DE60130014T2 (enExample) |
| DK (1) | DK1334964T3 (enExample) |
| ES (1) | ES2288997T3 (enExample) |
| MX (1) | MXPA03003575A (enExample) |
| PT (1) | PT1334964E (enExample) |
| RU (1) | RU2275354C2 (enExample) |
| TW (1) | TWI293290B (enExample) |
| WO (1) | WO2002034713A1 (enExample) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4116801A (en) * | 2000-03-17 | 2001-09-24 | Ajinomoto Kk | Drugs for complications of diabetes and neuropathy and utilization thereof |
| ES2290173T3 (es) * | 2000-10-18 | 2008-02-16 | Ajinomoto Co., Inc. | Procedimiento para la preparacion de acilfenilalaninas. |
| JP4114200B2 (ja) * | 2000-10-18 | 2008-07-09 | 味の素株式会社 | ナテグリニド結晶の製造方法 |
| AU2001296000A1 (en) * | 2000-10-24 | 2002-05-27 | Ajinomoto Co., Inc. | Nateglinide-containing hydrophilic drug preparations |
| BR0114896A (pt) * | 2000-10-24 | 2003-08-12 | Ajinomoto Kk | Preparação contendo nateglinida, e, método para produzir a mesma |
| EP1496048A4 (en) * | 2002-04-15 | 2006-08-02 | Ajinomoto Kk | NEW NATEGLINID CRYSTAL |
| US7411089B2 (en) | 2002-04-15 | 2008-08-12 | Ajinomoto Co., Inc. | Nateglinide crystals |
| US6861553B2 (en) | 2002-07-03 | 2005-03-01 | Teva Pharmaceuticals Industries Ltd. | Process for preparing nateglinide and intermediates thereof |
| US7358390B2 (en) | 2002-07-18 | 2008-04-15 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| US7148376B2 (en) | 2002-07-18 | 2006-12-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| US7420084B2 (en) * | 2002-07-18 | 2008-09-02 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| US7534913B2 (en) | 2002-07-18 | 2009-05-19 | Teva Pharmaceutica Industries Ltd. | Crystalline form of nateglinide |
| AU2003253971A1 (en) * | 2002-07-18 | 2004-02-09 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| ES2279921T3 (es) * | 2003-11-26 | 2007-09-01 | A.M.S.A. Anonima Materie Sintetiche E Affini S.P.A. | Procedimiento para la preparacion de nateglinida preferentemente en forma b. |
| US20060004102A1 (en) * | 2004-05-07 | 2006-01-05 | Shlomit Wizel | Polymorphic forms of nateglinide |
| WO2005110395A1 (en) * | 2004-05-19 | 2005-11-24 | University Of South Carolina | System and device for magnetic drug targeting with magnetic drug carrier particles |
| WO2005113485A2 (en) * | 2004-05-20 | 2005-12-01 | Dr. Reddy's Laboratories Ltd. | Stable nateglinide form b compositions |
| US7425648B2 (en) | 2005-01-03 | 2008-09-16 | A.M.S.A. Anonima Materie Sintetiche E. Affini S.P.A. | Process for the preparation of nateglinide, preferably in B-form |
| CN101111266A (zh) * | 2005-01-31 | 2008-01-23 | 味之素株式会社 | 含有降血糖药的用于改善或治疗糖耐量异常、临界性糖尿病、胰岛素抵抗性和高胰岛素血症的药物组合物 |
| WO2007135533A1 (en) * | 2006-05-23 | 2007-11-29 | Aurobindo Pharma Limited | Process for preparing nateglinide b-type crystals |
| KR100837843B1 (ko) * | 2006-12-26 | 2008-06-13 | 씨제이제일제당 (주) | 나테글리나이드 결정형, 그 제조방법, 및 그를 포함하는약제학적 조성물 |
| US9150499B2 (en) | 2010-06-14 | 2015-10-06 | Cipla Limited | Process for the preparation of nateglinide |
| US9303038B2 (en) | 2011-09-06 | 2016-04-05 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological diseases |
| SG11201407300VA (en) | 2012-05-07 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of neurological disorders |
| WO2013167990A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of depression |
| WO2013168021A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders |
| US9522884B2 (en) | 2012-05-08 | 2016-12-20 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic disorders |
| US9309233B2 (en) | 2012-05-08 | 2016-04-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of blood clotting disorders |
| WO2013167993A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological degenerative disorders |
| US9266823B2 (en) | 2012-05-08 | 2016-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of parkinson's disease |
| US9403826B2 (en) | 2012-05-08 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory disorders |
| CA2873084A1 (en) * | 2012-05-08 | 2013-11-14 | Cellixbio Private Limited | Compositions and methods for the treatment of diabetes |
| US9499526B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
| WO2013168015A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of asthma and allergy |
| WO2013167997A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
| WO2013168014A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of familial amyloid polyneuropathy |
| WO2013168001A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| WO2013167999A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurologic diseases |
| US9242939B2 (en) | 2012-05-10 | 2016-01-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
| US9233161B2 (en) | 2012-05-10 | 2016-01-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological conditions |
| US9339484B2 (en) | 2012-05-10 | 2016-05-17 | Cellix Bio Private Limited | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
| US9403857B2 (en) | 2012-05-10 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| US9273061B2 (en) | 2012-05-10 | 2016-03-01 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
| US9346742B2 (en) | 2012-05-10 | 2016-05-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of fibromyalgia pain |
| US9573927B2 (en) | 2012-05-10 | 2017-02-21 | Cellix Bio Private Limited | Compositions and methods for the treatment of severe pain |
| US9434729B2 (en) | 2012-05-23 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
| NZ701832A (en) | 2012-05-23 | 2016-08-26 | Cellix Bio Private Ltd | Compositions and methods for treatment of inflammatory bowel disease |
| JP2015518854A (ja) | 2012-05-23 | 2015-07-06 | セリックスビオ プライヴェート リミテッド | 多発性硬化症の治療のための組成物および方法 |
| SG11201407326XA (en) | 2012-05-23 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for treatment of mucositis |
| WO2013175376A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of local pain |
| WO2013175347A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
| US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| US9187427B2 (en) | 2012-08-03 | 2015-11-17 | Cellix Bio Private Limited | N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases |
| WO2014037833A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment inflammation and lipid disorders |
| AU2013311349A1 (en) | 2012-09-08 | 2014-11-27 | Cellixbio Private Limited | Compositions and methods for treatment of inflammation and lipid disorders |
| US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
| AU2014276346A1 (en) | 2013-06-04 | 2015-12-24 | Cellixbio Private Limited | Compositions and methods for the treatment of diabetes and pre-diabetes |
| US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
| SG11201706952VA (en) | 2014-09-26 | 2017-10-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of epilepsy and neurological disorders |
| EP3201168B1 (en) | 2014-09-29 | 2020-03-18 | Cellix Bio Private Limited | Compounds and compositions for the treatment of multiple sclerosis |
| AU2014414316B2 (en) | 2014-10-27 | 2020-04-09 | Cellix Bio Private Limited | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
| US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
| US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
| US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
| US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
| US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
| US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
| CN104402756B (zh) * | 2014-11-27 | 2016-08-31 | 天方药业有限公司 | 一种高纯度那格列奈的制备方法 |
| WO2016088132A1 (en) | 2014-12-01 | 2016-06-09 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
| US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
| JP6679616B2 (ja) | 2015-01-06 | 2020-04-22 | セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ | 炎症及び疼痛の治療のための組成物及び方法 |
| CN109369443A (zh) * | 2018-11-05 | 2019-02-22 | 扬子江药业集团江苏海慈生物药业有限公司 | 一种新的那格列奈h晶型的制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6354321A (ja) * | 1985-03-27 | 1988-03-08 | Ajinomoto Co Inc | 血糖降下剤 |
| AU615966B2 (en) * | 1987-12-04 | 1991-10-17 | Takeda Chemical Industries Ltd. | Crystals of cephem hydrochloride |
| DE10199058I2 (de) | 1991-07-30 | 2006-04-27 | Alcm Co | Kristalle von N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung |
| US5463116A (en) | 1991-07-30 | 1995-10-31 | Ajinomoto Co., Inc. | Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them |
| PT1586314E (pt) * | 1996-11-15 | 2011-07-01 | Ajinomoto Kk | Composição de comprimidos de nateglinida |
| US6844006B1 (en) * | 1999-07-09 | 2005-01-18 | Pennfield Oil Company | Process and apparatus for the preparation of chlortetracycline-containing animal feed compositions |
| PT1616561E (pt) * | 1999-12-28 | 2008-07-09 | Ajinomoto Kk | Preparação antidiabética para administração oral |
| AU4116801A (en) * | 2000-03-17 | 2001-09-24 | Ajinomoto Kk | Drugs for complications of diabetes and neuropathy and utilization thereof |
| JP4114200B2 (ja) * | 2000-10-18 | 2008-07-09 | 味の素株式会社 | ナテグリニド結晶の製造方法 |
| ES2290173T3 (es) * | 2000-10-18 | 2008-02-16 | Ajinomoto Co., Inc. | Procedimiento para la preparacion de acilfenilalaninas. |
| BR0114896A (pt) * | 2000-10-24 | 2003-08-12 | Ajinomoto Kk | Preparação contendo nateglinida, e, método para produzir a mesma |
| US7411089B2 (en) | 2002-04-15 | 2008-08-12 | Ajinomoto Co., Inc. | Nateglinide crystals |
-
2001
- 2001-10-23 DE DE60130014T patent/DE60130014T2/de not_active Expired - Lifetime
- 2001-10-23 AT AT01976819T patent/ATE370115T1/de active
- 2001-10-23 DK DK01976819T patent/DK1334964T3/da active
- 2001-10-23 BR BR0114846-0A patent/BR0114846A/pt not_active IP Right Cessation
- 2001-10-23 MX MXPA03003575A patent/MXPA03003575A/es active IP Right Grant
- 2001-10-23 CN CNB018212999A patent/CN100422143C/zh not_active Expired - Fee Related
- 2001-10-23 PT PT01976819T patent/PT1334964E/pt unknown
- 2001-10-23 KR KR1020037005671A patent/KR100810930B1/ko not_active Expired - Fee Related
- 2001-10-23 AU AU2001296001A patent/AU2001296001A1/en not_active Abandoned
- 2001-10-23 EP EP01976819A patent/EP1334964B1/en not_active Expired - Lifetime
- 2001-10-23 RU RU2003111948/04A patent/RU2275354C2/ru not_active IP Right Cessation
- 2001-10-23 JP JP2002537707A patent/JP4225057B2/ja not_active Expired - Fee Related
- 2001-10-23 CA CA002426745A patent/CA2426745C/en not_active Expired - Fee Related
- 2001-10-23 WO PCT/JP2001/009293 patent/WO2002034713A1/ja not_active Ceased
- 2001-10-23 ES ES01976819T patent/ES2288997T3/es not_active Expired - Lifetime
- 2001-10-24 TW TW090126305A patent/TWI293290B/zh not_active IP Right Cessation
-
2003
- 2003-04-24 US US10/421,888 patent/US20030229249A1/en not_active Abandoned
-
2007
- 2007-06-04 US US11/757,769 patent/US7544834B2/en not_active Expired - Fee Related
- 2007-08-28 CY CY20071101136T patent/CY1106839T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2426745A1 (en) | 2003-04-23 |
| TWI293290B (enExample) | 2008-02-11 |
| WO2002034713A1 (en) | 2002-05-02 |
| US7544834B2 (en) | 2009-06-09 |
| JPWO2002034713A1 (ja) | 2004-03-04 |
| EP1334964A4 (en) | 2005-09-28 |
| CA2426745C (en) | 2009-09-15 |
| DK1334964T3 (da) | 2007-09-24 |
| KR100810930B1 (ko) | 2008-03-10 |
| ES2288997T3 (es) | 2008-02-01 |
| BR0114846A (pt) | 2004-02-25 |
| ATE370115T1 (de) | 2007-09-15 |
| MXPA03003575A (es) | 2003-07-14 |
| CN100422143C (zh) | 2008-10-01 |
| JP4225057B2 (ja) | 2009-02-18 |
| AU2001296001A1 (en) | 2002-05-06 |
| US20030229249A1 (en) | 2003-12-11 |
| RU2275354C2 (ru) | 2006-04-27 |
| EP1334964B1 (en) | 2007-08-15 |
| DE60130014D1 (de) | 2007-09-27 |
| CN1483018A (zh) | 2004-03-17 |
| US20070232829A1 (en) | 2007-10-04 |
| KR20030059212A (ko) | 2003-07-07 |
| DE60130014T2 (de) | 2008-05-08 |
| EP1334964A1 (en) | 2003-08-13 |
| CY1106839T1 (el) | 2012-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1334964B1 (en) | Process for producing b-form nateglinide crystal | |
| PT1334963E (pt) | Processo para a produção de cristais de nateglinida | |
| BRPI0718178A2 (pt) | Processo para a preparação de sucralose pela cloração de açúcar com trifosgênio (btc). | |
| BRPI0615767A2 (pt) | processo melhorado para a preparação de compostos de aminodiol protegido por oxazolidina úteis como intermediários para florfenicol | |
| US3956493A (en) | Long acting tranquilizing agent | |
| PT97953B (pt) | Processo para a preparacao industrial da 4-cloro-3-sulfamoil-n-(2,3-di-hidro-2-metil-1h-1-indolil)-benzamida | |
| PT1334962E (pt) | ''processo de preparação de acilfenilalaninas'' | |
| BRPI0415019B1 (pt) | "processo para redução dos níveis de impurezas indesejáveis em uma amostra de mesotriona". | |
| Winstein et al. | Role of Neighboring Groups in Replacement Reactions. XIX. Polarimetric Acetolysis Rate of trans-2-Acetoxycyclohexyl p-Toluenesulfonate | |
| PT96051B (pt) | Processo melhorado para a preparacao de 2'-bromo-3,5-di-{n-dimetilcarbamoiloxi}-acetofenona, composto intermedio utilizado na preparacao do bambuterol | |
| JP4068702B2 (ja) | ペンタゾシンの光学異性体の分離法 | |
| Parke et al. | The preparation and properties of sodium d-pantothenate | |
| JP2739328B2 (ja) | ベンズイミダゾール化合物の精製方法 | |
| JP2949930B2 (ja) | 光学活性１−フェニル−２−（ｐ−トリル）エチルアミンの精製方法 | |
| JPH11343282A (ja) | カルバゾクロムスルホン酸誘導体の製法 | |
| PT87069B (pt) | Processo para a preparacao de 4-(6'-metoxi-2'-naftilmetil)-2,4-pentanodiona | |
| US2616896A (en) | Synthesis of tryptamine | |
| JP2641022B2 (ja) | ４，４’−ジヒドロキシジフェニルスルホンの精製法 | |
| JPH0259817B2 (enExample) | ||
| JP4005771B2 (ja) | アミノエチルフェノキシ酢酸誘導体の結晶多形 | |
| JPH0418084A (ja) | 光学活性２―メチルピペラジンの製造法 | |
| Jackson et al. | CERTAIN DERIVATIVES OF TETRABROMO-o-QUINONE. | |
| HK1192218A (en) | Preparation method and crystalline form iv of optical enantiomers of modafinil | |
| HK1192220A (en) | Preparation methods of forms of optical enantiomers of modafinil and pharmaceutical composition thereof | |
| ITRM950599A1 (it) | Processo per la cristallizzazione da acqua della s-n,n' -bis- ( 2-idrossi -1 -(idrossimetil) etil) -5- ((2 -idrossi -1- ossopropil) |